Fulvestrant

Fulvestrant is a steroidal estrogen receptor antagonist and selective estrogen receptor degrader used primarily in the treatment of hormone receptor-positive advanced or metastatic breast cancer. Unlike aromatase inhibitors, which reduce estrogen production, fulvestrant binds to estrogen receptors and promotes their degradation, thereby reducing estrogen receptor signaling in breast cancer cells. It is administered as a deep intramuscular injection, generally into the gluteal muscles. Fulvestrant is commonly used in postmenopausal patients and may be administered alone or as part of combination endocrine-based treatment with targeted anticancer medicines. Its clinical role is particularly important in hormone receptor-positive, HER2-negative advanced or metastatic breast cancer where endocrine therapy remains an important treatment approach. Fulvestrant received its initial United States approval in 2002, and subsequent regulatory expansions established its use in additional endocrine-treatment settings and combination regimens. Treatment selection depends on menopausal status, hormone receptor and HER2 status, previous endocrine therapy, disease progression, molecular characteristics, and the other medicines being considered. Because fulvestrant is given intramuscularly and undergoes hepatic metabolism, bleeding risk, liver function, injection technique, and concomitant treatments should be considered during therapy.

Fulvestrant was developed as a hormonal anticancer medicine designed to directly antagonize and reduce estrogen receptor activity. The United States Food and Drug Administration granted its initial approval in 2002 for hormone receptor-positive metastatic breast cancer in postmenopausal women with progression following antiestrogen therapy. Subsequent FDA labeling expansions included use in certain postmenopausal patients who had not previously received endocrine therapy and use in combination with CDK4/6 inhibitors such as palbociclib and abemaciclib for HR-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy. Fulvestrant received European Union marketing authorization through the European Commission in 2004. Its clinical development included randomized studies comparing fulvestrant with aromatase inhibitor therapy and later phase III programs evaluating combination treatment with targeted agents. Fulvestrant has also become an endocrine backbone in several approved combination regimens for selected patients with advanced HR-positive, HER2-negative breast cancer, including combinations involving targeted therapies directed at specific molecular or signaling pathways.

Fulvestrant is used for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, particularly in postmenopausal women, either as monotherapy in appropriate endocrine-treatment settings or in combination with targeted anticancer medicines. Approved combination uses include treatment with palbociclib or abemaciclib in patients with disease progression following endocrine therapy. Fulvestrant is also used as part of certain approved combination regimens with targeted agents, including capivasertib for selected HR-positive, HER2-negative advanced or metastatic breast cancer with specified PIK3CA, AKT1, or PTEN alterations and inavolisib with palbociclib for selected PIK3CA-mutated HR-positive, HER2-negative advanced or metastatic disease after endocrine resistance. Additional regulatory approvals may define its use with newer targeted agents in specific molecularly selected populations. In premenopausal or perimenopausal patients, ovarian function suppression may be required when fulvestrant is used in treatment regimens intended for patients whose ovarian estrogen production remains active.

Fulvestrant is administered by intramuscular injection into the gluteal region. The standard adult dose is 500 mg, administered as two injections, generally one in each buttock, on Days 1, 15, and 29, followed by administration once monthly thereafter. When used in combination with another anticancer medicine, the fulvestrant schedule generally remains based on this dosing regimen unless the applicable prescribing information specifies otherwise. In patients with moderate hepatic impairment, a reduced dose of 250 mg is recommended because systemic exposure may be increased. Fulvestrant should be administered slowly using appropriate intramuscular injection technique because of the risk of local injection-site complications and the proximity of the sciatic nerve. Treatment is generally continued until disease progression or unacceptable toxicity, with clinical assessment and laboratory monitoring performed according to the overall treatment regimen and the patient's condition.

Common side effects of fulvestrant include injection-site pain, nausea, bone pain, joint pain, headache, back pain, fatigue, pain in the extremities, hot flashes, vomiting, reduced appetite, weakness, musculoskeletal pain, cough, shortness of breath, and constipation. Increases in liver enzymes such as alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase may also occur. Injection-site discomfort can persist for a period after administration because the medicine is given intramuscularly. When fulvestrant is administered with targeted medicines such as CDK4/6 inhibitors or other anticancer agents, additional adverse effects related to the combination treatment may occur. The frequency and severity of side effects vary between patients and depend on disease status, other treatments, liver function, and individual susceptibility.

Important safety concerns include bleeding, hypersensitivity reactions, injection-site complications, increased drug exposure in patients with moderate hepatic impairment, and embryo-fetal toxicity. Because fulvestrant is administered intramuscularly, it should be used cautiously in patients with bleeding disorders, thrombocytopenia, or those receiving anticoagulant treatment. Injection into the gluteal region requires careful technique because of the proximity of the sciatic nerve, and injection-related sciatica, neuralgia, neuropathic pain, or peripheral neuropathy have been reported. Fulvestrant may cause fetal harm and should not be used during pregnancy unless specifically determined to be appropriate by a qualified healthcare professional. Hypersensitivity reactions, including urticaria and angioedema, can occur. Fulvestrant may also interfere with some serum estradiol immunoassays and produce falsely elevated results, which should be considered when interpreting hormone measurements.

Before treatment, clinicians should review pregnancy status where relevant, bleeding risk, platelet count, hepatic function, previous hypersensitivity reactions, and all concomitant medicines. Particular caution is appropriate in patients receiving anticoagulants or those with thrombocytopenia because fulvestrant is administered intramuscularly. Patients with moderate hepatic impairment require dose adjustment, while severe hepatic impairment has not been adequately studied. Females of reproductive potential should use effective contraception during treatment and for one year after the final dose according to current prescribing information. Fulvestrant itself has relatively limited potential for conventional cytochrome-mediated drug interactions because it is not primarily dependent on these pathways for metabolism, but clinically important interactions may arise from medicines administered in combination with it. When fulvestrant is combined with CDK4/6 inhibitors or other targeted therapies, monitoring should follow the safety requirements of the complete regimen. Estradiol laboratory results obtained using certain immunoassay methods should also be interpreted cautiously.

Confirm hormone receptor and HER2 status and review previous endocrine and targeted treatments before selecting fulvestrant. Assess hepatic function and bleeding risk before administration, particularly in patients receiving anticoagulants or those with thrombocytopenia. Use the recommended gluteal injection technique and administer the medicine slowly to reduce local complications and minimize the risk of sciatic nerve injury. When used in combination therapy, review the prescribing information and monitoring requirements of every component because toxicities may arise from the combination rather than fulvestrant alone. Treatment response should be assessed using appropriate clinical and radiological criteria, with therapy generally continued while disease remains controlled and treatment is tolerated. Be aware that fulvestrant can interfere with certain estradiol immunoassays, which may complicate interpretation of hormone measurements. Counsel patients about injection-site discomfort, reproductive precautions, and symptoms that should be reported promptly.